# A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides

Study · id `cardio:ct-nct01262638` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01262638](<https://clinicaltrials.gov/study/NCT01262638>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01262638

Browse, organ or system: Metabolism  
Browse, condition area: Risk and prevention; Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 177 participants.

## Technical summary

Registry record NCT01262638. Randomized; quadruple masking; primary purpose treatment. Start 2010-12 (registry gives no type); primary completion 2011-08-23 (actual). Results posted on 2021-03-16.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 177 participants (enrolled count; ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Start date: 2010-12 (registry gives no type) (ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Primary completion: 2011-08-23 (actual) (ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Completion: 2011-08-23 (actual) (ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Results first posted: 2021-03-16 (ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT01262638, source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01262638-2021-03-17`, retrieved 2026-10-31)

## The registry's words

- Brief title: A Study to Assess the Efficacy and Safety of ETC-1002 in Subjects With Elevated Blood Cholesterol and Either Normal or Elevated Triglycerides
- Condition: Dyslipidemia
- Intervention (Drug): ETC-1002
- Intervention (Drug): Placebo
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

### Other papers using this trial's data

- Registry lists this paper as a reference of type result; PubMed dates it on or after the trial start and types it as a trial report, neither its types nor its title mark it as a protocol, a review or a comment, the paper names no other trial in place of this one, and PubMed shows no retraction or expression of concern; it is not marked as the trial's main report: Efficacy and safety of a novel dual modulator of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase in patients with hypercholesterolemia: results of a multicenter, randomized, double-blind, placebo-controlled, parallel-group trial (`cardio:pubmed-23770179`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: a65d76cb6a3a61fd99dffed8f8f4265c5c81ec6034c510f9cd8073d0f2e9d638
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
